UBS Maintains a 'Buy' on Omnicare (OCR); After the Call: Shaking Things Up
Tweet Send to a Friend
UBS maintains a 'Buy' on Omnicare (NYSE: OCR), lowers PT from $36 to $28.
UBS analyst says, "Interim CEO spent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "Interim CEO spent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
